NCT02059499 2025-07-23
Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
AIDS Malignancy Consortium
Phase 3 Completed
Clinical Trials
25 trialsNCT03196180 2025-04-08
Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia
National Cancer Institute (NCI)
Phase EARLY_PHASE1 Completed
NCT01926496 2025-03-07
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
LEO Pharma
Phase 4 Completed
NCT02078648 2025-02-03
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT04883645 2025-01-28
Neoadjuvant Imiquimod Immunotherapy for Oral Cancer
Medical University of South Carolina
Phase EARLY_PHASE1 Completed
NCT02135419 2024-07-26
ANCHOR
AIDS Malignancy Consortium
Phase 3 Completed
NCT02864147 2024-05-02
Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)
Yale University
Phase 2 Completed
NCT03180684 2023-08-25
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Inovio Pharmaceuticals
Phase 2 Completed
NCT00142454 2022-10-10
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT01421017 2021-11-18
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases
NYU Langone Health
Phase 1/2 Completed
NCT03914417 2021-01-20
Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02482428 2021-01-05
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
Phase 2 Completed
NCT01686152 2020-11-24
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
Teva Pharmaceuticals USA
Phase 3 Completed
NCT00948428 2020-09-04
Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldaraâ„¢ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis
Actavis Inc.
Phase 3 Completed
NCT02224599 2020-04-24
Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
Kiromic BioPharma Inc.
Phase 1/2 Terminated
NCT02120898 2019-12-13
A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses
Actavis Inc.
Phase 3 Completed
NCT00988559 2018-07-09
Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00504023 2018-06-06
Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT00979550 2018-03-22
The Effects of Aldara as an Adjunct to Laser Treatment
University of Kentucky
Phase 2 Terminated
NCT00774787 2016-11-07
Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses
Rigel Dermatology
Phase 4 Completed
NCT00899574 2015-12-07
Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
NYU Langone Health
Phase 2 Completed
NCT01203878 2014-12-08
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
Tennessee Clinical Research Center
Phase 4 Terminated
NCT00828568 2014-01-28
Bioequivalence Study of Two Imiquimod Cream 5%
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed
NCT00273910 2012-10-19
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00674739 2011-05-24
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
Graceway Pharmaceuticals, LLC
Phase 3 Completed